Is CORT a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

604 people get CORT articles and Market Currents by email alert.

Get email alerts on CORT »

HEADLINES:

Corcept Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Corcept Therapeutics Announces First Quarter 2013 Financial Results

Marketwire (May 2, 2013)
Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call

Marketwire (Apr 26, 2013)
2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward
C.R. Jackson • Wed, Apr 17 • 5 Comments
Corcept Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results

Marketwire (Mar 7, 2013)
2 $2 Biotech Stocks Insiders Are Buying
Bret Jensen • Fri, Mar 1 • 16 Comments
Corcept Therapeutics' CEO Corporate Revenue Update (Transcript)
Thu, Feb 14
Corcept Therapeutics Announces Fourth Quarter and Full Year Revenue and Corporate Update

Marketwire (Feb 12, 2013)
3 Small Cap Movers With Similar Trends But Different Outlooks
Teresa Dawn • Wed, Jan 23 • 3 Comments
Corcept Begins Recovery After Disastrous Launch Of Korlym
Brian L. Wilson • Tue, Jan 8 • 1 Comment
Insider Buying Highlights Reasons I Took A Flyer On This $1.40 Pharma Stock
Bret Jensen • Tue, Dec 4, 2012 • 15 Comments
5 Healthcare Companies With Insider Buying During November 2012 - Part III
Markus Aarnio • Fri, Nov 9, 2012 • 6 Comments
Corcept Therapeutics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012
Corcept Focuses On Stress Hormone
C.R. Jackson • Wed, Oct 31, 2012 • 5 Comments
Corcept Therapeutics Announces Third Quarter Results and Corporate Update

Marketwire (Oct 31, 2012)
Corcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors

Marketwire (Oct 15, 2012)
ThinkEquity Analyst Bets On Extraordinary Science And Clinical Data
Life Sciences Report • Thu, Sep 20, 2012
5 Highly-Liquid Healthcare Stocks With Growth On The Horizon
ZetaKap • Wed, Sep 12, 2012 • 1 Comment
3 Liquid Biotech Stocks With Impressive Growth Projections
ZetaKap • Sun, Aug 12, 2012
Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility

Marketwire (Aug 7, 2012)

To learn more about Seeking Alpha Pro, click here.

Corcept Begins Recovery After Disastrous Launch Of Korlym
Brian L. Wilson • Tue, Jan 8 • 1 Comment
Insider Buying Highlights Reasons I Took A Flyer On This $1.40 Pharma Stock
Bret Jensen • Tue, Dec 4, 2012 • 15 Comments
Corcept Focuses On Stress Hormone
C.R. Jackson • Wed, Oct 31, 2012 • 5 Comments
Corcept Therapeutics: Korlym Is Available Now
Roy Manning III • Thu, Apr 26, 2012 • 1 Comment
Corcept Therapeutics: Is There More To Come?
M. E. Garza • Thu, Feb 23, 2012 • 1 Comment
Corcept Scores A First With Cushing's Treatment Approval In The U.S.
EP Vantage • Tue, Feb 21, 2012 • 1 Comment
Catalysts On Tap For Corcept Therapeutics
Brian L. Wilson • Tue, Feb 7, 2012 • 3 Comments
Corcept Still Down but Positive Phase III Results Herald Potential Gains in 2011
M. E. Garza • Mon, Dec 27, 2010 • 4 Comments
Interview: Corcept Therapeutics CFO on Corlux Phase 3 Results
M. E. Garza • Fri, Dec 17, 2010 • 2 Comments
December Will Be Exciting for Up and Coming Corcept Pharmaceuticals
Sheff Station • Mon, Nov 29, 2010 • 4 Comments
Corcept Stock Continues To Rally On Weight Loss News
H.S. Ayoub • Wed, Jun 27, 2007
Corcept's Crash Not Necessarily What it Seems
Fredric Cohen, M.D. • Mon, Aug 28, 2006

2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward
C.R. Jackson • Wed, Apr 17 • 5 Comments
2 $2 Biotech Stocks Insiders Are Buying
Bret Jensen • Fri, Mar 1 • 16 Comments
3 Small Cap Movers With Similar Trends But Different Outlooks
Teresa Dawn • Wed, Jan 23 • 3 Comments
5 Healthcare Companies With Insider Buying During November 2012 - Part III
Markus Aarnio • Fri, Nov 9, 2012 • 6 Comments
ThinkEquity Analyst Bets On Extraordinary Science And Clinical Data
Life Sciences Report • Thu, Sep 20, 2012
5 Highly-Liquid Healthcare Stocks With Growth On The Horizon
ZetaKap • Wed, Sep 12, 2012 • 1 Comment
3 Liquid Biotech Stocks With Impressive Growth Projections
ZetaKap • Sun, Aug 12, 2012
7 Fast Growth Healthcare Stocks With Generous Reserves
ZetaKap • Tue, Jul 31, 2012 • 1 Comment
6 Healthcare Stocks Positioned For High Growth
ZetaKap • Fri, Jul 20, 2012 • 1 Comment
Hedge Funds Are Buying These 10 High-Growth Biotech Stocks
Kapitall • Sat, Jul 14, 2012
8 High Growth Small Caps With Analyst Love
ZetaKap • Wed, Jun 20, 2012
10 Rallying Stocks Under $5 Being Bought Up By Hedge Funds
Kapitall • Sun, Jun 17, 2012 • 1 Comment
10 Rallying Biotech Stocks Being Snapped Up By Hedge Funds
Kapitall • Tue, Jun 12, 2012 • 1 Comment
7 Growing Biotech Small Caps With Strong Analyst Confidence
ZetaKap • Mon, Jun 11, 2012 • 2 Comments
7 Stocks Deeply Discounted From Target Price Seeing Short Covering
Kapitall • Tue, Mar 27, 2012
4 Biotech Stocks Trading At A Steep Discount To Target Price
Kapitall • Sun, Mar 4, 2012 • 5 Comments
9 Biotech Stocks With Significant Liquidity Growth
Kapitall • Fri, Mar 2, 2012 • 1 Comment
3 Rallying Biotech Stocks Short Sellers Expect To Underperform
Kapitall • Thu, Mar 1, 2012 • 5 Comments
12 Healthcare Companies Expecting Major February Catalysts
Spencer Knight • Wed, Feb 1, 2012 • 8 Comments
9 Biotech Stocks Being Snapped Up By Company Insiders
Kapitall • Sun, Nov 6, 2011 • 1 Comment

Corcept Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Corcept Therapeutics' CEO Corporate Revenue Update (Transcript)
Thu, Feb 14
Corcept Therapeutics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012

Corcept Therapeutics Announces First Quarter 2013 Financial Results

Marketwire (May 2, 2013)
Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call

Marketwire (Apr 26, 2013)
Corcept Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results

Marketwire (Mar 7, 2013)
Corcept Therapeutics Announces Fourth Quarter and Full Year Revenue and Corporate Update

Marketwire (Feb 12, 2013)
Corcept Therapeutics Announces Third Quarter Results and Corporate Update

Marketwire (Oct 31, 2012)
Corcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors

Marketwire (Oct 15, 2012)
Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility

Marketwire (Aug 7, 2012)
Corcept Therapeutics Announces Second Quarter Results and Corporate Update

Marketwire (Aug 7, 2012)
Corcept Therapeutics Announces Underwritten Public Offering of Common Stock

Marketwire (Jul 2, 2012)
Corcept Therapeutics Commences Public Offering of Common Stock

Marketwire (Jul 2, 2012)
Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update

Marketwire (May 3, 2012)
Corcept Therapeutics Announces National Product Launch of Korlym(TM) for Patients With Endogenous Cushing's Syndrome

Marketwire (Apr 10, 2012)
UPDATE: Data Published in Premier Endocrinology Journal Shows Korlym(TM) Provides Significant Clinical Improvement in Patients With Endogenous Cushing's Syndrome

Marketwire (Apr 9, 2012)
Corcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants

Marketwire (Mar 26, 2012)
Korlym(TM) (mifepristone), the First Approved Medication for Patients With Endogenous Cushing's Syndrome, to Be Available by April 11

Marketwire (Mar 22, 2012)
Movers & Shakers: Tuesday’s biggest gaining & declining stocks

at MarketWatch.com (Feb 21, 2012)
FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym(TM) for Cushing's Syndrome

Marketwire (Dec 15, 2011)

CORT vs. ETF Alternatives

Company Description

Currently, there's no company description for CORT.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 3, 6:50 AM Corcept Therapeutics (CORT): Q1 EPS of -$0.10 misses by $0.01. Revenue of $1.72M misses by $0.76M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 7, 5:23 PM More on Corcept Therapeutics (CORT): Q4 is largely in-line on EPS, but a bit shy on the revenue side. Net profit declined Y/Y, as the drug developer racked up higher SG&A expenses due to increased staffing, consultancy and other professional services costs related to the rollout of Korlym. Comment! [Healthcare, Earnings]
Thursday, March 7, 5:17 PM Corcept Therapeutics (CORT): Q4 EPS of -$0.09 in-line. Revenue of $1.4M misses by $0.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, January 4, 4:05 PM Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an upgrade yesterday by Piper Jaffray and analysts at Janney Capital beginning coverage of the stock with a Buy rating and a $3 price target. CORT climbed just over 10% on Thursday to close at $1.63 a share, its best finish since early November. Comment! [Healthcare, On the Move]
Tuesday, December 4, 2012, 12:45 PM Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move]
Tuesday, August 7, 2012, 9:10 AM Premarket gainers: USHS +37%. BSFT +24%. FOSL +21%. LOPE +18%. BVSN +10%. ZLCS +10%. VRNG +9%. IHG +8%. CIM +6%. NOK +6%. MGM +5%. DCTH +5%.
Losers: WMS -20%. LEAP -18%. NIHD -16%. ELN -11%. CORT -10%. HEK -9%. DUF -8%. Comment! [On the Move]
Monday, July 2, 2012, 9:10 AM Premarket gainers: CELL +64%. LNCR +21%. AMPE +17%. ATPG +13%. WFR +9%. AMLN +9%. MU +7%.
Losers: ANH -6%. OREX -5%. CORT -5%. Comment! [On the Move]
Monday, July 2, 2012, 8:38 AM Corcept Therapeutics (CORT) intends to sell 11M shares to raise funds for R&D and other purposes. Corcept develops drugs for severe psychiatric and metabolic disorders, including Cushing's syndrome and psychotic depression. Shares -5.35% premarket. (PR) Comment! [Healthcare, On the Move]
Friday, June 29, 2012, 12:41 PM ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning: Navidea (NAVB +3.7%), BioMarin (BMRN +4.5%), Corcept Therapeutics (CORT +4%), Medivation (MDVN +5.2%), Amicus Theraputics (FOLD +2%), Raptor Pharmaceuticals (RPTP +0.2%), Synageva BioPharma (GEVA +3.2%), Aegerion (GEVA +3.7%). Comment! [Healthcare, On the Move]
Thursday, March 22, 2012, 11:01 AM Leerink Swann says the pricing for Corcept's (CORT -0.8%) Korlym is higher than expected at $186 per 300mg tablet, which should help offset its caution regarding patient numbers. The drug developer announced this morning it will begin shipping Korlym starting April 11. 1 Comment [Healthcare]
Tuesday, February 21, 2012, 9:07 AM Premarket gainers: CORT +61%. THLD +59%. PBH +24%. CTIC +11%. CHG +10%. STM +8%. SWC +8%. JASO +7%. WYNN +6%. IVAN +6%. SSN +5%. YGE +5%. HL +4%. IRE +4%. TSL +4%. FRO +3%. M +3%. HD +3%. DANG +3%. CS +3%. STP +3%. NG +3%.
Losers: GTXI -39%. CHTP -13%. WFT -11%. CTRP -9%. CIE -5%. NBG -5%. RIG -5%. CIEN -4%. WMT -3%. Comment! [On the Move]
Tuesday, February 21, 2012, 6:56 AM Corcept Therapeutics (CORT) continues to skyrocket after landing FDA approval for its Korlym oral medicine used to treat Cushing's syndrome patients. The firm expects to launch of Korlym within the next two to three months, with consensus sales forecasts for the drug running as high as $409M by 2016. Shares +68.1% premarket. Comment! [On the Move, Healthcare]
Friday, February 17, 2012, 4:45 PM Corcept Therapeutics (CORT), a specialty drug company that hasn’t generated revenue since 2009, wins FDA approval for its Korlym treatment that uses the active ingredient of the abortion pill RU-486 to treat Cushing’s Syndrome. Shares +42.5% after a trading halt. Comment! [Healthcare, On the Move]
Thursday, June 30, 2011, 11:56 AM Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively. Comment! [On the Move, Healthcare]
Monday, June 6, 2011, 8:53 AM A massive data dump this morning and over the weekend from biotech firms reporting results from various drug trials and regulatory updates. Stocks on the move as a result: Cell Therapeutics (CTICD, press release) +2.8%, Exelixis (EXEL, PR) -2.2%, Incyte (INCY, PR) +3%, Corcept Therapeutics (CORT, PR) -4.8%, United Therapeutics (UTHR, PR) -6.1%, RXi Pharmaceuticals (RXII, PR) +17.7%, Impax Labs (IPXL, PR) -3.3%. Comment! [Healthcare, On the Move]

Scott Matusow
Trade and buy Alert, Bought $CORT at 2.00, target opinion per chart = $2.50 short term.
Jan 25, 1:22 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

eliaa123
$CORT way up today!
Jan 4, 4:07 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Highly-Liquid Healthcare Stocks With Growth On The Horizon http://bit.ly/OqsvnM $CORT $CPIX $DNDN $DUSA $PMTI @ZetaKap
9/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

anonymous#12
CORT, korlym sales seemed pretty weak taking in consideration it is a orphan drug indication. Neutral.
8/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
3 Liquid Biotech Stocks With Impressive Growth Projections http://bit.ly/NrEmOe $ANIK $CBPO $CORT @ZetaKap
8/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Fast Growth Healthcare Stocks With Generous Reserves http://bit.ly/QdI4wS $SRDX $CPIX $IMGN $MELA $QLTI $VVUS $CORT @ZetaKap
7/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh
7/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
7/26/12
• !Report Abuse
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
7/26/12
• !Report Abuse
Add a reply...

140 characters

ZetaKap
6 Healthcare Stocks Positioned For High Growth http://bit.ly/OMUbMU $CORT $ISIS $MELA $CYBX $PACB $EBS @ZetaKap
7/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
8 High Growth Small Caps With Analyst Love http://bit.ly/NPm8Zn $ACTV $BEBE $BONA $CORT $ELLI $LQDT $NPSP $NQ @ZetaKap
6/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Growing Biotech Small Caps With Strong Analyst Confidence http://bit.ly/OlxAd8 $ANIK $CRTX $CTIC $BSTC $CERS $EBS $CORT @ZetaKap
6/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh
7/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
7/26/12
• !Report Abuse
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
7/26/12
• !Report Abuse
Add a reply...

140 characters

CORT Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated